Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsJames B. Yu, MD, MHS, FASTRO
he/him/his
Assistant Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Assistant Professor Adjunct
Biography
James Yu, MD, MHS, is Professor of Radiation Oncology and Genitourinary Cancers Radiotherapy Lead at Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire.
He is a former Professor of Radiation Oncology at the Yale School of Medicine, former Associate Chief Medical Officer of the Smilow Cancer Hospital and Care Centers and Executive Vice Chair of Columbia University Irving Medical Center Department of Radiation Oncology.
In his academic work, Dr. Yu conducts research on ways to use radiotherapy treatments to improve outcomes for cancer patients. “We need to push the field ever forward and not be satisfied with merely prolonging survival,” says Dr. Yu. “I think radiosurgery will play a role in this. As systemic therapies improve and our ability to control microscopically disseminated disease improves, noninvasive ablative therapies will become ever more important.”
As a former Yale Center for Clinical Investigation scholar and founding member of the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale, Dr. Yu’s research centers on the comparative effectiveness of new radiation technologies and how these new technologies are adopted nationally.
Dr. Yu is the Editor-in Chief of JNCI Cancer Spectrum, Deputy Editor-In-Chief of the journal Practical Radiation Oncology and is on the editorial boards of the Journal of Clinical Oncology - Clinical Cancer Informatics, JNCI, Journal of Surgical Oncology, and Oncology (Williston Park), and former editorial board member of the Journal of Clinical Oncology.
He has published over 350 original manuscripts and co-edited the textbook Pocket Radiation Oncology and Principles of Clinical Cancer Research. He is the radiation oncology co-chair for the Southwest Oncology Group Genitourinary Cancers Committee, and a nationally recognized expert in patient reported outcomes.
Last Updated on March 10, 2025.
Appointments
Medical Oncology and Hematology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- Brain Tumor Center
- COPPER Center
- Gamma Knife Center
- Internal Medicine
- Medical Oncology and Hematology
- Pituitary Program
- Prostate & Urologic Cancers Program
- Radiation Oncology
- Yale Cancer Center
- Yale Ventures
- Yale-BI Biomedical Data Science Fellowship
Education & Training
- MHS
- Yale University, Masters of Health Science (2014)
- Resident
- Yale New Haven Hospital (2009)
- Chief Resident
- Yale School of Medicine (2009)
- MD
- University of Michigan Medical School (2004)
- BS
- Yale University (1999)
Research
Copy Link
Overview
Medical Research Interests
Breast Neoplasms; Central Nervous System Neoplasms; Head and Neck Neoplasms; Radiotherapy, Intensity-Modulated; Urogenital Neoplasms
ORCID
0000-0002-3119-3226
Research at a Glance
Yale Co-Authors
Frequent collaborators of James B. Yu's published research.
Publications Timeline
A big-picture view of James B. Yu's research output by year.
Research Interests
Research topics James B. Yu is interested in exploring.
Henry S. Park, MD, MPH
Veronica Chiang, MD, FAANS
Cary P Gross, MD
Sanjay Aneja, MD
Jeph Herrin, PhD
Victor Lee, MD
191Publications
4,587Citations
Breast Neoplasms
Radiotherapy, Intensity-Modulated
Head and Neck Neoplasms
Publications
2026
Early-Stage Lung Cancer Treatment Disparities by Race Among Medicare Beneficiaries
Lynch O, Lee D, Soulos P, Yu J, Herrin J, Gross C. Early-Stage Lung Cancer Treatment Disparities by Race Among Medicare Beneficiaries. JAMA Network Open 2026, 9: e2559845. PMID: 41770564, PMCID: PMC12954539, DOI: 10.1001/jamanetworkopen.2025.59845.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMedicare beneficiariesRacial disparitiesStereotactic body radiotherapyWhite patientsBlack patientsNon-Hispanic white patientsEarly-stage NSCLCCancer treatment disparitiesLung cancer careCurative treatmentSEER-Medicare dataReceipt of surgeryCancer careSurgical treatmentDiagnosis of stage IRetrospective cohort studyMain OutcomesTreatment disparitiesSEER-MedicareCohort studyMedicareRacial differencesDisparitiesEnd ResultsAdjusted probabilityIntegrating Locoregional Therapies into Oncology Value Frameworks to Improve Patient-Centered Decision Making and Outcomes
Asare K, Corn B, Ennis R, Sapir E, Kapadia N, Gross C, Yu J. Integrating Locoregional Therapies into Oncology Value Frameworks to Improve Patient-Centered Decision Making and Outcomes. Practical Radiation Oncology 2026 PMID: 41771435, DOI: 10.1016/j.prro.2026.02.009.Peer-Reviewed Original ResearchAltmetricConceptsLocoregional therapyTreatment modalitiesLocal tumor controlLocal treatment modalitiesOrgan function outcomesPatient-centered decision makingLocoregional interventionsTumor controlSystemic therapyDrug treatmentFunctional outcomesOrgan preservationTherapeutic benefitTherapyHospitalization ratesOncologyModalitiesTreatmentOutcomesLocoregionallyFORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide
Nguyen P, Kollmeier M, Rathkopf D, Hoffman K, Zurita A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, McKay R, Rose B, Shin K, Kibel A, Taplin M. FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide. European Urology 2026 PMID: 41672869, DOI: 10.1016/j.eururo.2025.12.001.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPSA progression-free survivalMetastasis-free survivalProstate-specific antigenSalvage radiotherapyMulticenter randomized trialGnRH agonistAbiraterone acetate plus prednisoneMetastasis-free survival ratesAcetate plus prednisoneProgression-free survivalMedian Follow-UpHigh-risk featuresStandard treatment optionDetectable prostate-specific antigenRadical prostatectomyAbiraterone acetatePN statusPrimary endpointSecondary endpointsSafety profileAdverse eventsTreatment optionsFollow-upApalutamidePreplanned analysisIncidence of breast implant–associated anaplastic large cell lymphoma
Lowe L, Kim D, Rohde C, Yu J, Cheng S, Kachnic L, Horowitz D, Neugut A, Kinslow C. Incidence of breast implant–associated anaplastic large cell lymphoma. Journal Of The National Cancer Institute 2026, djag019. PMID: 41570109, DOI: 10.1093/jnci/djag019.Peer-Reviewed Original ResearchAltmetricConceptsBreast implant-associated ALCLAnaplastic large cell lymphomaAge-adjusted incidence ratesBreast implant-associated anaplastic large cell lymphomaImplant-associated anaplastic large cell lymphomaU.S. standard populationSurveillance, EpidemiologyAge-adjusted incidenceEnd Results ProgramLarge cell lymphomaFood and Drug AdministrationStandard populationResults ProgramCell lymphomaDiagnostic codesProvisional entityWorld Health OrganizationBreast implantsDrug AdministrationAdult womenHealth OrganizationBreastLymphomaEpidemiologyWomenLow-Dose Radiotherapy for Osteoarthritis: Current Evidence, Practical Recommendations and Future Perspectives
Schlamann A, Yu J, Rühle A. Low-Dose Radiotherapy for Osteoarthritis: Current Evidence, Practical Recommendations and Future Perspectives. Seminars In Radiation Oncology 2026, 36: 39-47. PMID: 41391897, DOI: 10.1016/j.semradonc.2025.07.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsLow-dose radiotherapyPatient selectionRisk of radiation-induced malignancyAbsolute riskShort follow-up durationStandard dosing regimensPlacebo-controlled studyRadiation-induced malignancyFollow-up durationNoninvasive therapeutic optionProportion of patientsSuboptimal patient selectionFavorable safety profileAnti-inflammatory effectsRandomized Controlled TrialsDose planningDosing regimensLow-doseRetrospective studySafety profileTherapeutic optionsPharmacological therapyClinical evidenceOptimal doseRandomized trials
2025
Association between rectal spacer use and bowel, urinary, and sexual dysfunction following prostate cancer brachytherapy: U.S. claims data analysis
Folkert M, Weg E, Sato R, Yu J, Bhattacharyya S, Ezekekwu E, Hamstra D. Association between rectal spacer use and bowel, urinary, and sexual dysfunction following prostate cancer brachytherapy: U.S. claims data analysis. Brachytherapy 2025, 25: 402-409. PMID: 41392003, DOI: 10.1016/j.brachy.2025.10.015.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsSpacer useProstate cancerBaseline dysfunctionSexual dysfunctionRectal spaceAssociated with significantly lower incidenceBeam radiation therapyMedian Follow-UpSignificant lower incidenceCox proportional hazards modelsProstate cancer brachytherapyReal-world studyProportional hazards modelBT modalitiesBT monotherapyLDR patientsLDR-BTRectal spacerMonotherapy patientsRadiation therapyCancer brachytherapyClaims data analysisSecondary cancersUrinary dysfunctionRetrospective studyProstate-Specific Membrane Antigen PET for Patients With Postoperative Recurrence of Prostate Cancer
Kamran S, Yu J, Kapadia N. Prostate-Specific Membrane Antigen PET for Patients With Postoperative Recurrence of Prostate Cancer. JAMA Oncology 2025, 11: 1438-1439. PMID: 41037277, DOI: 10.1001/jamaoncol.2025.3625.Peer-Reviewed Original ResearchAltmetricRacial and Ethnic Diversity of the Oncology Workforce: Projections From 2020 to 2060
Roberts W, Soulos P, Herrin J, Pollack C, Genao I, Yu J, Boatright D, Gross C. Racial and Ethnic Diversity of the Oncology Workforce: Projections From 2020 to 2060. JCO Oncology Practice 2025, 21: 1877-1885. PMID: 41074755, DOI: 10.1200/op-25-00876.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsUS populationPhysician workforceCulturally competent careAssociation of American Medical CollegesAmerican Indian/Alaska NativePhysician recruitmentCancer physiciansCompetent careOncology workforceAmerican Medical CollegesIndian/Alaska NativeAmerican Medical AssociationMedical AssociationURiMRace groupsWorkforcePhysiciansPopulation shareMedical CollegeEthnic diversityRepresentation ratiosEthnic distributionWorkforce compositionPopulationAssociationThe Comparative Toxicity of Focal Ablation Versus Intensity Modulated Radiation Therapy for Prostate Cancer
Yu J, DeStephano D, Jeffers B, Tward A, Spina C, Horowitz D, Wang T, Kachnic L, Soulos P, Gross C, Cheng S. The Comparative Toxicity of Focal Ablation Versus Intensity Modulated Radiation Therapy for Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2025, 124: 937-948. PMID: 40998272, DOI: 10.1016/j.ijrobp.2025.09.020.Peer-Reviewed Original ResearchCitationsAltmetricConceptsIntensity modulated radiation therapyFocal ablative therapyProstate cancerRadiation therapyGastrointestinal toxicityFT patientsRectal bleedingIMRT patientsHigher risk of incontinenceHigh riskAndrogen deprivation therapyStandard radiation therapyRisk of incontinenceMonths of treatmentSEER-Medicare databaseGenitourinary toxicityAndrogen deprivationGenitourinary complicationsAblation therapyFocal ablationIncontinence therapyTreatment modalitiesLogistic regression modelsCancer characteristicsSEER-MedicareAnaplastic Large Cell Lymphoma of the Breast by Race and Ethnicity
Kim D, Lowe L, Neugut A, Yu J, Cheng S, Kachnic L, Horowitz D, Rohde C, Kinslow C. Anaplastic Large Cell Lymphoma of the Breast by Race and Ethnicity. JAMA Network Open 2025, 8: e2528013. PMID: 40892414, PMCID: PMC12406062, DOI: 10.1001/jamanetworkopen.2025.28013.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAge-adjusted incidence ratesAnaplastic large cell lymphomaPersons per yearIncidence rateLarge cell lymphomaT-cell lymphomaCohort studyPopulation-based cohort studyEstimates of incidence ratesAmerican IndiansPacific IslandersSurveillance, EpidemiologyCell lymphomaWhite patient populationPrimary anaplastic large cell lymphomaCases of T-cell lymphomaComplications associated with breast implantsAlaska NativesMain OutcomesWhite patientsBlack patientsBlack populationCohortPatient populationT cells
Academic Achievements & Community Involvement
Copy Link
Honors
honor Fellow
07/17/2023National AwardAmerican Society for Radiation OncologyDetailsUnited Stateshonor Cancer Prevention and Control Research Prize
12/31/2017Yale School of Medicine AwardYale Cancer CenterDetailsUnited Stateshonor Population Research Prize
11/22/2013Yale School of Medicine AwardYale Cancer CenterDetailsUnited Stateshonor Seattle Prostate Brachytherapy Fellow
01/01/2009National AwardAmerican Brachytherapy SocietyDetailsUnited Stateshonor Young Oncologist Essay Award
01/01/2008National AwardAmerican Radium SocietyDetailsUnited States
News
Copy Link
News
Get In Touch
Copy Link
Contacts
Email